Found 49 ne-neurology trials
A listing of ne-neurology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Featured study
ABBV-CLS-7262 is a prodrug that is converted in vivo to the pharmacologically active parent compound A-1684909. A-1684909 is a central nervous system (CNS)-penetrant, eukaryotic translation initiation factor 2B (eIF2B) activator that attenuates the integrated stress response (ISR), a highly conserved cellular mechanism hypothesized to be important in the pathophysiology of …
Since its launch in 2004, the overarching aim of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI1, ADNI-GO, and ADNI2 studies that have been combined public/private collaborations between academia and industry to determine the …
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's …
The study is at the Penn Memory Center at the University of Pennsylvania and is under the direction of David Wolk, M.D.. We are currently recruiting normal control participants ages 75 years and older. The purpose of this study is to collect, store and analyze cognitive data and biological samples, …
This is a Phase 3 study of rozanolixizumab in anti-AChR or anti-MuSK autoantibody-positive patients with generalized MG who experience moderate to severe symptoms and are being considered for treatment with IVIg or PEX. The primary objective of the study is to demonstrate the clinical efficacy of rozanolixizumab in patients with …
The purpose of this study is to continue to obtain information from people with and without Parkinson disease (PD) so that researchers may better understand how Parkinson disease progresses, in order to inform better treatments. The information collected in this study is for research and not for clinical care. This …
Blood pressure treatment is important for all survivors of intracerebral hemorrhage (ICH). High blood pressure after ICH puts patients at high risk for future strokes and memory problems. Nearly all doctors agree that patients who have had a brain hemorrhage should be treated with blood pressure medications. But doctors are …
Rozanolixizumab is a humanized IgG4 monoclonal antibody that is being developed as an inhibitor of the activity of the neonatal Fc receptor (FcRn) for IgG. By blocking the activity of neonatal FcRn, rozanolixizumab accelerates the catabolism of antibodies and reduces the serum IgG concentration, including pathogenic IgG in MG patients, …
Primary Progressive Aphasia, or PPA, is a neurodegenerative disease that affects language abilities. A person with PPA may have difficulties speaking, understanding speech, reading, or writing, and these difficulties worsen over time.The purpose of this study is to determine whether a form of non-invasive brain stimulation called High-definition Transcranial Direct …
The purpose of this research study is to evaluate new tests for Parkinson's disease (PD) that may help in developing better treatments.
Please choose between Voice or SMS based delivery of verification code
or